HOME >> MEDICINE >> NEWS
'Vioxx like' drugs may still be best option for arthritis, write scientists

Scientists believe that despite the current concerns around anti-inflammatory drugs like Vioxx, they may still be the best option for treating some forms of arthritis.

In a Nature Reviews of Drug Discovery article this month the researchers from Imperial College London and Queen Mary, University of London examine the use of selective inhibitors of cyclo-oxygenase-2 (COX-2).

They argue that although this class of drugs, which includes Vioxx, has been associated with an increase in the risk of cardiovascular events such as heart attacks and strokes in some patients, the same may be true for traditional non-steroid anti-inflammatory drugs (NSAIDs).

All NSAIDs, including COX-2 inhibitors, work by blocking the actions of both COX-1 and COX-2 enzymes. Blocking COX-2 relieves inflammation and pain, but blocking COX-1 can increase the risk of gastric ulcers and bleeds. For this reason COX-2 selective drugs were developed with the simple aim that they would retain the therapeutic actions of NSAIDs (linked to inhibition of COX-2) but lose the gastric side effects (linked to inhibition of COX-1).

The researchers reviewed over one hundred papers on the subject and looked at the latest recommendations from organisations such as the American Federal Drugs Administration on the use of COX-2 inhibitors and NSAIDs.

The researchers point out that the calls for the removal of COX-2 inhibitors, and a return to using NSAIDs, may cause additional problems. Although NSAIDs have been marketed for a number of years, they have never been required to meet the clinical trial standards now set for COX-2 inhibitors, meaning they may not be any safer.

Professor Jane Mitchell, from Imperial College London, and one of the reviews authors, said: "Although some COX-2 drugs have been reported to increase the risk of heart attack and stroke, they may still remain the best option for treating arthritis in some patients without cardiovascular risk facto
'"/>

Contact: Tony Stephenson
at.stephenson@imperial.ac.uk
44-207-594-6712
Imperial College London
18-Jan-2006


Page: 1 2

Related medicine news :

1. UIC researchers to develop new drugs to fight bioterrorism
2. Statin drugs may delay progressive artery damage in children
3. Study finds HIV protease inhibitor drugs may adversely affect the scaffolding of the cell nucleus
4. Experts call for urgent research into anti-epileptic drugs given to children
5. UCLA researchers develop new nanomaterials to deliver anti-cancer drugs to cells
6. Antipsychotic drugs increase risk of death in older people with dementia
7. Antipsychotic drugs increase risk of death in older people with dementia
8. Gene variations point to why lung cancer drugs work better in Japanese vs. US patients
9. Panel offers guidelines on skin reactions to new class of cancer drugs
10. Blood-thinning drugs need closer monitoring
11. Comparison of patients access to new and better cancer drugs reveals inequalities between countries

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Vioxx like drugs may still best option for arthritis write scientists

(Date:8/3/2015)... ... August 03, 2015 , ... Illinois Health & Science (IHS) ... , The acquisition includes all of IBAM NA’s cyclotron sites and research and ... a robust regionally located business, as well as a large manufacturing hub in Noblesville, ...
(Date:8/3/2015)... , ... August 03, 2015 , ... ... Programs, with accountability for overall performance of the company’s Medicare and Federal Employee ... of Cambia’s strategy to deliver better health for members. In this role, Scott ...
(Date:8/3/2015)... ... 03, 2015 , ... Did you know that there are thousands of ... affordable home care options which A-1 Home Care Agency specialize in? In fact, diversity, ... A-1 Home Care Agency is known for. , With all ...
(Date:8/2/2015)... ... ... many “would be” entrepreneurs, starting a new business can prove to be daunting from ... business.” Neither needs be a major obstacle. , The U.S. has always been the ... be successful. The risks of starting a business can be high but the rewards can ...
(Date:8/1/2015)... ... August 02, 2015 , ... Back packs can be dangerous? Whaaat?! , ... packs can wreck havoc on a kid's spine. With school starting again, most kids ... school. Make sure you are aware of how to help them prevent injuries by ...
Breaking Medicine News(10 mins):Health News:Illinois Health & Science Expands Nuclear Medicine Footprint With Purchase of IBA Molecular North America, Inc. 2Health News:Cambia Health Solutions Names Scott Powers President of Government Programs 2Health News:A-1 Home Care in Los Angeles and Orange County Honors Exceptional Office Staff 2Health News:A-1 Home Care in Los Angeles and Orange County Honors Exceptional Office Staff 3Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 2Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 3Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 4Health News:Newport Board Group, an Advisory Firm Serving Middle Market Companies, Releases a 5 Step Guide to Starting a Successful Business for Under $1,000 5Health News:Local AlignLife Doctor Donates Time to Check Back Packs 2
(Date:7/31/2015)... 31, 2015 Quietly, sedately, Morocco,s ... the domestic pharmaceutical industry is strong, with a well-developed ... high international standards. One place where the ... sub-Saharan Africa: Morocco has quietly become the second largest ... Africa . Indeed, Moroccan pharma companies have been ...
(Date:7/31/2015)... July 31, 2015  Semler Scientific, Inc. (Nasdaq: ... services to healthcare insurers and physician groups, today reported ... 2015. "In the second quarter of ... revenue growth of 54%, quarter over quarter revenue growth ... installed base of FloChec® units of 18%," said Doug ...
(Date:7/31/2015)... -- Xencor, Inc. (NASDAQ: XNCR ), a clinical-stage biopharmaceutical ... autoimmune diseases, asthma and allergic diseases, and cancer, today ... to its board of directors. "Yujiro,s ... a tremendous asset to our board," said Bassil ... Xencor. "Xencor faces a range of opportunities for our ...
Breaking Medicine Technology:PharmaBoardroom Releases New Morocco Pharmaceuticals Report 2PharmaBoardroom Releases New Morocco Pharmaceuticals Report 3Semler Reports Second Quarter 2015 Financial Results 2Semler Reports Second Quarter 2015 Financial Results 3Semler Reports Second Quarter 2015 Financial Results 4Semler Reports Second Quarter 2015 Financial Results 5Semler Reports Second Quarter 2015 Financial Results 6Xencor Appoints Yujiro S. Hata to Board of Directors 2Xencor Appoints Yujiro S. Hata to Board of Directors 3
Cached News: